Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TESTAT1: Testosterone replacement after allogeneic HSCT
jRCT1031250146Phase 1Recruiting
- Sponsor
- University of Tsukuba Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of testosterone enanthate in hematopoietic malignancies, Hematopathy and Hypoandrogenism (TD), sponsored by University of Tsukuba Hospital. Primary endpoint: Safety and tolerability of testosterone (all adverse events related to testosterone administration). Started Dec 2025; status: recruiting.
02
Drugs
testosterone enanthate
03
Conditions
hematopoietic malignanciesHematopathyHypoandrogenism (TD)
Beyond the preview
Go deeper on jRCT1031250146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250146.